The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | Exciting results from CARTITUDE-1: anti-BCMA CAR-T for MM
Ciltacabtagene autoleucel (cilta-cel; formerly JNJ-4528) is CAR T-cell therapy containing two BCMA-targeting single-domain antibodies designed to confer avidity. Jesus Berdeja, MD, Director of Myeloma Research, Sarah Cannon Research Institute, Nashville, TN, discusses the results from the CARTITUDE-1 trial (NCT03548207), a Phase Ib/II study of cilta-cel in patients with relapsed and/or refractory multiple myeloma (MM). Dr Berdeja highlights the very exciting results, including measurable residual disease (MRD) negativity in all evaluable patients tested and a manageable safety profile. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
